Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Licenses Eclipse Dark Quencher Technology to Applied Biosystems for Environmental Testing

NEW YORK, Sept. 17 (GenomeWeb News) - Epoch Biosciences of Bothell, Wash., today announced that it has licensed its Eclipse-brand dark quencher technology to Applied Biosystems.


Epoch will supply ABI its technology for integration into ABI's TaqMan probes for use in 5' nuclease assays. The license agreement covers ABI's use of the quencher technology for detection of microorganisms in the environment, Epoch said.


Epoch will receive license fees and royalties on sales of TaqMan probes containing its technology.


The Eclipse dark quencher technology helps improve signals in DNA probes by suppressing signals generated by fluorescent dyes.


Epoch has licensed the technology to ABI for use in other TaqMan products, as well as to Amersham Biosciences, Qiagen, Takara, Glen Research, and Third Wave Technologies.


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.